MedTrace Logo

Subthalamic Nucleus Deep Brain Stimulation in Speech Study

NCT05493670 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2023-12-22

No results posted yet for this study

Summary

Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN) have unpredictable and varied speech outcomes after this treatment. Our research will prospectively document speech performance before, during and 6- and 12-months after STN-DBS in 80 surgically treated patients and compared with 40 non-surgical controls with Parkinson's disease. This study will provide unique insights into the role of STN in speech production, document speech outcome in a comprehensive fashion, identify factors that predict functional communication ability 12 months after STN-DBS, and test the feasibility of low frequency DBS in reversing DBS-induced speech declines in order to optimize treatment strategies for those living with Parkinson's disease.

Conditions

  • Parkinson Disease
  • Dysarthria

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Pittsburgh

    collaborator OTHER

  • University at Buffalo

    collaborator OTHER

  • Northwestern University

    collaborator OTHER

  • National Institute on Deafness and Other Communication Disorders (NIDCD)

    collaborator NIH

  • Jeremy Greenlee

    lead OTHER

Principal Investigators

  • Jeremy Greenlee, MD · University of Iowa Dept of Neurosurgery

Eligibility

Min Age
21 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05493670 on ClinicalTrials.gov